NCT01260129 - Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH | Biotech Hunter

Enrollment

424

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

October 31, 2011

Conditions

Benign Prostatic Hypertrophy

Interventions

DRUG

Silodosin

Silodosin 8 mg orally, once daily after morning meal

DRUG

Silodosin

Silodosin 4 mg orally, twice daily after morning and evening meal

Trial Locations (14)

The Catholic Univ., Bucheon ST.Mary's Hospital, Bucheon-si

Busan National Univ. Hospital, Busan

Konkuk Univ, Chungju Hospital, Chungju

Choongnam National Univ. Hospital, Daejeon

Eulji Univ. Hospital, Daejeon

Chonnam Univ. Hospital, Hwasun

Inha Univ. Hosipital, Incheon

Asan Medical Center, Seoul

Chungang Univ. Hospital, Seoul

Korea Univ. Hospital, Seoul

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

Severance Hospital, Seoul

The Catholic Univ., Seoul ST.Mary's Hospital, Seoul